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Abstract 
 
The human papillomavirus (HPV) is the most widespread sexually transmitted infection in 
America. College-aged students are a high-risk group for HPV transmission, but their HPV 
vaccination rates are low. The purpose of this evidence-based project was to implement an HPV 
vaccination program at a health science center university student health clinic to increase 
vaccination rates to meet the guidelines of the American College Health Association (ACHA) 
and the Centers for Disease Control and Prevention (CDC). The objectives of this project were as 
follows: 1) to educate providers and staff on the importance of the HPV vaccine; 2) to increase 
HPV vaccine recommendations to students by providers and staff; 3) to increase the HPV 
vaccination rate among students offered the vaccine; and 4) to increase the vaccination rate 
among all eligible students. Prior to implementation, 100% of staff were educated on the HPV 
vaccination guideline, resulting in a 33% improvement in test scores between pre- and post-tests. 
Of 205 student visits, 10.7% were recommended the vaccine. Sixty-four percent of students who 
were offered the vaccine accepted the immunization. The overall clinic vaccination rate post-
implementation was 4.5%. Limitations of the project included staffing issues, problems with 
staff completing the education in a timely manner, providers’ perceptions of time constraints, 
students not remembering their HPV vaccine status, and a lack of knowledge around insurance 
coverage for the vaccine. The vaccination of even one previously unimmunized student can slow 
the spread of HPV; therefore, this project affected practice and patient outcomes through 
implementation of an HPV vaccination program, increasing HPV vaccination rates in an at-risk 
population.  
Keywords: human papillomavirus vaccine, human papillomavirus 
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Implementation of the Human Papillomavirus Vaccine Among Health Professions Students  
The Human Papillomavirus (HPV) is the most widespread sexually transmitted infection 
in America (Centers for Disease Control and Prevention [CDC], 2017). It affects 79 million 
Americans every year in the form of oropharyngeal and cervical cancers as well as genital warts. 
HPV can also cause vulvar, vaginal, penile, or anal cancers (CDC, 2017). It is transmitted via 
oral, vaginal, or anal sex with another person who is harboring the virus. In many cases, infected 
men and women exhibit no symptoms.  
The Food and Drug Administration has approved an HPV vaccine as a means of 
preventing HPV-related conditions. The public tends to have a limited understanding of the 
importance of the vaccine. Some believe the HPV vaccine is only for young women from 11 to 
26 years old; however, young men within this age range can receive the vaccine as well. Some 
parents feel the vaccine is not necessary for their children and contend that it may encourage 
sexual activity; nevertheless, vaccination in childhood is intended to prevent HPV-related 
cancers and genital warts later in life. Some individuals believe the HPV vaccine may be harmful 
despite having been Food and Drug Administration approved. Thus, vaccine-related education, 
provider encouragement, and staff collaboration are needed to increase the rate of HPV 
vaccination among eligible individuals. 
Statement of the Problem 
HPV is the most common sexually transmitted infection. Approximately 80 million 
people have HPV, and 14 million are estimated to become infected with the virus each year 
(CDC, 2016). HPV has over 150 strains, six of which can contribute to oropharyngeal, anal, 
cervical, vaginal, vulvar, and penile cancers in men and women (CDC, 2016; Osazuwa-Peters et 
al., 2017). About 70% of sexually active individuals are infected with HPV, which has been 
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prominently linked with cervical cancer (Dominiak-Felden et al., 2013). The two HPV genotypes 
responsible for 73% of cervical cancers are strains 16 and 18 (CDC, 2016). The incidence of 
cervical cancer has increased in women under 50 years old. Over 300,000 women pass away 
from cervical cancer each year, approximately 4,000 of whom live in the United States (CDC, 
2016). In addition to cervical cancer, HPV strains 6 and 11 lead to genital warts. The remaining 
five strains—31, 33, 45, 52, and 58—cause an additional 15% of cervical cancers (CDC, 2016).  
The current recommendation is to vaccinate boys and girls ages 11 to 12 (Cohen & Legg, 
2014). A Healthy People 2020 goal is to increase cervical cancer prevention, measured as 80% 
of eligible candidates receiving the HPV vaccination at an early age (Osazuwa-Peters et al., 
2017; Ratanasiripong, Cheng, & Enriquez, 2013). However, if an individual has not received the 
HPV vaccine by college age, then the three-dose series should be encouraged. University clinics 
provide an ideal venue for administration.  
Some individuals may consider university students too old to receive the vaccine, 
assuming it is too late for them to be vaccinated; accordingly, HPV vaccination rates are much 
lower in this population. The American College Health Association has stated that approximately 
35% of men and 55% of women in college stated they had received at least one dose of the HPV 
vaccine (as cited in Vázquez-Otero et al., 2016). This finding supports low HPV vaccination 
rates among the college-aged population although most individuals within this age range are 
sexually active. For example, in one study, nearly 78% of students surveyed reported having 
engaged in sexual intercourse (Marchand, Glenn, & Bastani, 2012). College students are 
therefore at high risk of transmitting and contracting HPV (Cohen & Legg, 2014).  
Government officials have not prioritized the HPV vaccine for social and political 
reasons. Rumors abound that the HPV vaccine will increase sexual activity and lead teens and 
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young adults to have more sexual partners. Many religious and social groups have therefore 
spurned this vaccine. Many state higher education institutions also do not have policies 
mandating HPV vaccination; thus, more education and awareness is needed to increase public 
acceptance and understanding of the importance of the HPV vaccine. 
There are many reasons for low HPV vaccination completion rates among college 
students (Rashid, Labani, & Das, 2016). For example, many university students may not have 
had a chance to receive the vaccine as pediatric patients. If they were offered the vaccine, their 
parents may have refused the vaccination or were not provided sufficient information to make an 
informed decision regarding vaccination. Due to the fast pace and lack of time in clinics, 
healthcare providers face various obstacles to thoroughly educating patients about the HPV 
vaccine. At the university level, students can make their own medical decisions without parental 
consent (Barnard, George, Perryman, & Wolff, 2017). Therefore, better awareness and education 
regarding the HPV vaccine is imperative to increasing immunization rates among eligible 
university students (Cohen & Legg, 2014; Marchand, Glenn, & Bastani, 2012).  
Background and Significance 
 Approximately 14 million young adults are infected with HPV annually, and nearly half 
the population will come into contact with HPV at some point in their lives (CDC, 2016; 
McCave, Chertok, Winter, & Haile, 2013). Each year, 19,200 women and 11,600 men are 
diagnosed with an HPV-related cancer in the United States HPV-associated oropharyngeal 
cancers are most common in men, with 9,100 men diagnosed in America every year (CDC, 
2017). Cervical cancer is the third most common cancer caused by HPV; 12,000 women in the 
United States are diagnosed with it annually. Of all HPV-related diseases, cervical cancer is the 
most serious female condition. It is most common in women, especially those who are sexually 
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active (Ndikom & Ofi, 2012). Oropharyngeal cancer is the sixth most common HPV-related 
disease, causing 70% of cases in women and men. Prevention of these and other HPV-related 
conditions through administration of the HPV vaccine can potentially protect thousands of men 
and women (including those already infected with HPV) from serious and possibly fatal cancers. 
The major HPV vaccine available to prevent cervical cancer in the United States is the 9-
valent/9vHPV or Gardasil 9 vaccine (CDC, 2017). Merck manufactures Gardasil 9 (and 
previously the quadrivalent, Gardasil 4); GlaxoSmithKline produced Cervarix, a bivalent 
vaccine, until 2016. Gardasil 4 debuted in June 2006 and was initially available for young 
women before being approved for use in young men in October 2009; it covered HPV strains 6, 
11, 16, and 18. In 2006, the National Advisory Committee on Immunization Practices in the 
United States recommended the vaccine for girls ages 11 to 12. The bivalent vaccine, Cervarix, 
was released in October 2009 for young women and covered HPV strains 16 and 18 (Dominiak-
Felden et al., 2013).  
These vaccines have since been replaced by Gardasil 9, which covers both sexes from 9 
to 26 years of age and protects against strains 6, 11, 16, 18, 31, 33, 45, 52, and 58. Men between 
22 and 26 years old are only recommended to receive the vaccination if they are 
immunocompromised or have homosexual partners (CDC, 2017). Gardasil 9 can prevent up to 
80% of cervical cancers worldwide (CDC, 2017), and in trials for vaccine approval, it was nearly 
100% effective in preventing cervical, vulvar, and vaginal diseases caused by the five additional 
HPV types (31, 33, 45, 52, and 58) (Chatterjee, 2014). Since the end of 2016, most clinics have 
begun using Gardasil 9 to vaccinate eligible individuals who consent to receive the vaccine. 
Contraindications for the HPV vaccine include the potential for Cervarix to cause anaphylaxis in 
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individuals allergic to latex, whereas the Gardasil types carry the risk of an increased reaction in 
individuals allergic to yeast. 
HPV vaccination rates are low for many reasons, including speculation that the vaccine 
promotes sexual activity; thus, many parents of college students do not advocate for the vaccine 
prior to their children leaving home (Ratanasiripong et al., 2013). Additionally, there is a low 
completion rate of the three-dose series among those who have received the HPV vaccine, with 
minorities having a lower completion rate than other groups. African-American women have the 
highest death rate from cervical cancer (Galbraith et al., 2016). African-Americans are also the 
least educated about the HPV vaccine compared to non-Hispanic whites, who are more willing to 
receive the vaccine when offered (Osazuwa-Peters et al., 2017). Many minority parents 
mistakenly believe that their child will contract HPV from the vaccine. Another discrepancy is 
prevalent among college-aged women, 70% of whom report being sexually active while less than 
50% have completed the three-dose HPV vaccination course at 0, 1–2, and 6 months 
(Ratanasiripong et al., 2013).  
A lack of understanding and awareness of the devastation associated with cervical cancer 
has led to many problems (Marchand, Glenn, & Bastani, 2012). The first HPV vaccine was 
released over 10 years ago, yet many college students have not been vaccinated. Factors such as 
cost, insufficient access to care, and poor public awareness partially explain why individuals do 
not take advantage of this preventative option to protect against cervical cancer. Other 
individuals are nervous about receiving the vaccine due to a lack of knowledge about its benefits 
(Remes, Smith, Alvarado-Llano, Colley, & Levesque, 2014). The HPV vaccine requires a three-
dose series and thus necessitates patient effort to ensure completion. If the series is initiated prior 
to age 15, only two doses are necessary, rendering earlier vaccination more efficacious. Another 
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issue involves informing the patient that the HPV vaccine is due, especially for the three-dose 
series. Notification methods, such as electronic reminders through a patient portal, have been 
shown to increase course completion among patients in the primary care setting (Wright et al., 
2011).  
Increasing the rate of HPV vaccination depends on patients’ perceptions of the vaccine 
and associated marketing strategies. Choosing not to vaccinate will reduce the protection the 
HPV vaccine provides the population (Osazuwa-Peters et al., 2017; Simms et al., 2016). Thus, 
cervical cancer may result in higher rates of morbidity and mortality. Also, the lack of a mandate 
for the vaccine contributes to low HPV vaccination rates. The government can assist in 
increasing vaccination by requiring individuals between 9 and 26 years old who do not want the 
vaccine to opt out in lieu opting in for the vaccine. Opting out occurs when an individual must 
specifically state he or she does not want a vaccine.  
Additional efforts must be devoted to marketing the HPV vaccine to promote and 
increase HPV vaccination rates. The incidence of HPV-related oropharyngeal and anal cancers in 
men is rising, but men are less aware of the HPV vaccine than women (Osazuwa-Peters et al., 
2017). Not all providers routinely recommend the HPV vaccine, and many parents have stated 
that if a provider does not recommend that their son or daughter receive the vaccine, then they 
are less likely to have their child vaccinated (McRee, Gilkey, & Dempsey, 2014). Providers may 
not recommend the vaccine for several reasons: time constraints; difficulty advocating for sexual 
health, especially to parents of young children; absence of data regarding long-term side effects 
of the vaccine; and the fact that HPV vaccination is not mandatory. Providers also tend to 
recommend the vaccine to women more than men (McRee et al., 2014). Lastly, even when 
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providers recommend the vaccine, some parents will use avoidance strategies to circumvent their 
child’s vaccination (e.g., stating they wish to delay the HPV vaccine to a subsequent visit).  
Assessment 
The location for this evidence-based project was a south-central Texas health science 
center university student health clinic. The university clinic provides primary care services (e.g., 
annual physicals, immunizations, and blood work), care for acute illnesses and minor injuries, 
and health promotion services to approximately 3,000 students. All students are required to carry 
either university-offered health insurance or another form of health coverage. Five nurse 
practitioner providers work varying hours in the clinic along with a registered nurse (RN), 
licensed vocational nurses (LVNs), and two medical assistants (MAs). The clinic is nurse-
managed by a physician who serves as the delegating physician per Texas law. The clinical 
manager reported that the clinic engages in about 8,000 encounters annually. Eighty-four percent 
of patients seen in the clinic are students in their twenties, and most are women. The 
predominant ethnicities are Caucasian and Hispanic. Many patients who come to the clinic have 
their own transportation. The most common reasons for visitation are immunizations and 
allergies.  
Although many visits are related to immunizations, a microsystem assessment conducted 
in Spring 2016 demonstrated that the HPV vaccine was not routinely recommended to students 
because the clinic did not stock the vaccine. If a student wanted the vaccine, then he or she 
would be instructed to go to a local pharmacy or another primary care provider who offered it. 
For many students, the student health clinic serves as their primary care provider while attending 
school; therefore, the student has two providers. Many students within the eligible age range for 
the HPV vaccine were also being missed because they were assumed to have received the 
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vaccine while living at home. Moreover, providers did not regularly address the need for the 
HPV vaccine during appointments, especially annual physicals. During an observed clinic day, 
two women were encouraged to receive the HPV vaccine because they were younger than age 
26; however, men seen during the same time frame were never offered the vaccine. 
The microsystem assessment also revealed that the clinic’s electronic medical records 
system had no way to alert the provider that a student was eligible for the HPV vaccine; there 
was also no manual way to notify the provider of the need for the vaccine. Because the vaccine 
was not being regularly offered, no mechanism was in place to assist students in remembering to 
come for the remaining doses in the HPV series. Furthermore, even though the university is a 
healthcare-focused education institution, no pamphlets or information on the HPV vaccine were 
available either in the clinic or on the university website to increase student awareness. The 
availability of such materials would allow students to become educated about the vaccine and 
make an informed decision on whether to receive it. Lastly, at the university level, no electronic 
hold on a student’s account prevented him or her from registering, as is customary for other 
immunizations, because the HPV vaccine is not mandatory.  
One benchmark for the HPV vaccine in college-aged students is the American College 
Health Association (ACHA) guidelines. The ACHA guidelines refer to the CDC as a resource 
for more information, offering recommendations for immunizations within the college setting. 
Regarding the HPV vaccine, all women between 11 and 26 years old should be vaccinated with 
the bivalent, quadrivalent, or 9-valent vaccine. Men between 11 and  21 years old should receive 
the quadrivalent or 9-valent vaccine, as should men who have sex with other men or those who 
are immunocompromised and between 11 and 26 years of age (ACHA, 2017).  
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The HPV vaccine should be available as a three-dose series (administered at 0, 1–2, and 6 
months) in the college setting for young adults who have not been vaccinated. The clinic should 
prioritize implementation of an HPV vaccination program because thousands of potentially 
eligible students may be at risk for cervical and oropharyngeal cancers as well as genital warts if 
they are not vaccinated against HPV. Texas has not mandated the HPV vaccine as it has for other 
immunizations, thereby lowering immunization rates. On February 2, 2007, then-governor Rick 
Perry signed an executive order that would have mandated that all girls entering the 6th grade 
receive the HPV vaccine; however, the Texas governor reversed his stance shortly thereafter 
amid criticism from conservative Texans.  
Organization Readiness for Change and Stakeholder Engagement 
 Upon review of the ACHA guidelines and the results of a Spring 2016 microsystem 
assessment, it was determined that the stakeholders in the organization were ready for change. 
Numerous talks with the clinical manager and the Dean of the School of Nursing indicated that 
both advocated for offering the HPV vaccine at the student health clinic. All parties agreed that 
providing the vaccine would be imperative to primary care provided at the university student 
health clinic. By offering the HPV vaccine, students could obtain the three necessary doses. The 
clinical manager supported stocking the clinic with the HPV vaccine and implementing a 
marketing campaign to spread awareness about it. All providers and staff expressed their support 
of the plan to begin to vaccinate individuals who consented to receive the HPV vaccine. Policy-
making was also part of the plan and was conducted in collaboration with a panel of individuals 
integral to the launching of the HPV vaccination program in the student health clinic.  
In summary, there was an identified deficit in the student health clinic regarding the 
prevention of HPV-related illnesses due to the on-site unavailability of the HPV vaccine. 
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Documentation presented another problem: students who had received the HPV vaccine were not 
labeled as such through their student records, and those who had not received the vaccine were 
not identified and could number in the thousands. Many students younger than 26 years who 
were eligible to receive the vaccine could not receive it in the student clinic. Although students 
could visit a local pharmacy to receive the vaccine along with corresponding documentation in 
their school vaccination record, this process was inconvenient and seldom offered. Health 
insurance (whether school-provided or private) covers preventative vaccines, including the HPV 
vaccine. Thus, the cost of the vaccine was not a barrier to program implementation because the 
clinic would bill most insurance companies. 
Project Identification 
Purpose  
The purpose of this evidence-based project was to implement an HPV vaccination 
program at a health science center university student health clinic to increase vaccination rates to 
meet the guidelines of ACHA and the CDC. The project represents a primary care initiative to 
prevent future HPV-related diseases such as cervical and oropharyngeal cancers.  
Objectives 
The objectives of this project were as follows:  
1. One hundred percent of providers and staff would be educated on the importance of the 
HPV vaccine and the new HPV vaccination program in the clinic.  
2. Provider recommendations for the HPV vaccine to eligible students would increase from 
0% initially to 50% post-implementation. 
3. The number of eligible students offered the HPV vaccine who received a dose would 
increase from 0% initially to 50% post-intervention.  
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4. The HPV vaccination rate among eligible students who visited the student health clinic 
would increase from 0% initially to 60% post-intervention.  
Anticipated Outcomes 
The anticipated short-term outcome for this project was an increased HPV vaccination 
rate among students attending the university, increased awareness and education around the HPV 
vaccine among students at the university, and an increase in recommendations by providers, with 
staff collaboration, for the HPV vaccine to eligible students. In addition, upon completion of the 
implementation period, the clinic would align with Healthy People 2020 goals and the ACHA 
and CDC guidelines. The anticipated long-term outcome was the prevention of HPV-related 
diseases, thereby decreasing morbidity and mortality.  
Summary and Strength of the Evidence 
Extensive research has addressed implementing the HPV vaccine in various 
environments. Studies have demonstrated which methods were successful and where 
improvements were needed. Data from these studies are summarized herein. Lander, Besson, 
Rodrigues, Audureau, and Saba (2014) reported that implementing the HPV vaccine in low-
income countries using a no-cost method was highly effective. However, vaccination rates were 
better when supply was uninterrupted; a consistent supply eliminated delays in administering the 
vaccine (Ladner, Besson, Rodrigues, Audureau, & Saba, 2014). Thus, having the logistics in 
place to ensure the student clinic had a consistent vaccine supply was important. Ladner et al. 
(2014) also suggested that the best way to increase HPV vaccination rates was to establish a 
school-based vaccination program where students could receive each of the three required doses 
on campus (Ladner et al., 2014).  
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Many factors contribute to a college student’s willingness to begin and complete the HPV 
vaccine series. Marchand, Glenn, and Bastani (2012) found that among 178 community college 
female students in Los Angeles, 43% demonstrated a three-dose completion rate, with students 
who were studying a health-related major or were younger being more likely to start the vaccine 
series. Another study examining the behaviors of Hispanic college women revealed that if a 
student was obese and had not received the flu vaccine or scheduled a Pap smear in the past 12 
months, she was less likely to receive the HPV vaccine (Cohen & Legg, 2014).  
Alexander et al. (2014) investigated how best to encourage awareness and increase 
vaccination rates among teen men. The authors suggested that awareness should focus on how 
HPV is transmissible between partners. Emphasizing the negative consequences of not receiving 
the vaccine was found to be more effective than stating the usual positive remarks about the 
vaccine (Alexander et al., 2014). Lastly, Dominiak-Felden et al. (2013) stated that HPV 
vaccination rates would increase if the message focused on the fact that the HPV vaccine 
prevents genital warts and anal, oral, and penile cancers. Thus, messaging to develop awareness 
should focus on the lack of life quality when a person is diagnosed with HPV-related lesions or 
neoplasms (Dominiak-Felden et al., 2013).  
Many researchers have concurred that completion of the three-dose series is low 
compared to the already low initiation rate among the eligible population (Alexander et al., 
2014). When the HPV vaccine was encouraged along with screenings for other sexually-
transmitted diseases like HIV, the vaccination completion rate increased (McCave et al., 2013). 
Electronic reminders via a healthcare portal or similar system, at an interval that does not 
overwhelm patients, has also been shown to promote vaccination completion (Wright et al., 
2011).  
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Between-group comparisons have revealed differences in HPV vaccination rates. 
Disparities persist among minority populations and Caucasians in terms of receiving and being 
aware of the HPV vaccination (Marchand et al., 2012; Osazuwa-Peters et al., 2017). The 
Caucasian population was also more likely to receive and complete the HPV vaccination course 
than their minority counterparts (Ratanasiripong et al., 2013). Regarding other demographics, 
men are less likely to be vaccinated against HPV than women (McCave et al., 2013). Younger 
eligible patients are more likely to receive the vaccine than those who are older, as the latter 
group may believe it is too late to be vaccinated. Thus, promotional efforts should target 
individuals who are older, low-income, minority, or male to increase vaccination rates among the 
eligible population.  
Methods 
Project Intervention 
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The vaccination process in the implementation plan was initiated either when an eligible 
student requested or a provider offered the HPV vaccine to patients from 18 to 27 years old. 
Although the eligible age criteria for receiving the HPV vaccine at the time of this study was 9 to 
26 years old, 27-year-old students were considered candidates in the case at least one dose had 
been received before age 26 and the series needed to be completed. Next, the provider and 
student discussed the HPV vaccine to determine eligibility. If the student was eligible but 
declined the vaccine despite provider-based education, the reason for refusal was documented in 
the student’s electronic health record. If the student agreed to be vaccinated, he or she then 
signed a consent form indicating an understanding of the risks and benefits of the HPV vaccine. 
The student was also given a Vaccine Information Sheet. After the RN or LVN administered the 
HPV vaccine, the front desk staff or MA scheduled the student for a nurse visit to receive the 
next HPV vaccine dose; a wallet-size reminder card (see Figure 2) was provided to remind the 
student about his or her next HPV vaccination nurse visit.  
 
 
Figure 2. Wallet-size reminder. 
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The HPV vaccine implementation plan was based on the Plan, Do, Check, and Act cycle. 
A new component of the intervention was introduced every other week to increase the HPV 
vaccination rate among university health professions students. Week 1 included staff education 
on the HPV checklist (see Figure 3). Week 2 reinforced the previous week. Week 3 reminders 
using the CDC advertising marketing campaign were posted on computer terminals in an area 
visible to providers. Week 4 provided reinforcement of the posted reminders on clinic computer 
terminals (see Figure 4). In Week 5, students in the clinic waiting room were offered an 
immunize.org flyer as a handout; the flyer was also used as an email marketing tool, distributed 
to all university health professions students, to encourage students to receive the vaccine. Weeks 
6 through 8 focused on reinforcement of all intervention components. 
Figure 3. HPV checklist. 
 
  







Figure 4. Computer terminal reminder. 
During every week of the HPV vaccine implementation period, the DNP student 
performed an audit of providers’ patient loads to identify students eligible for the vaccine. Each 
provider was then assessed to determine the percentage of students offered and subsequently 
given the HPV vaccine. If a provider had not completed the HPV checklists or initiated the 
conversation with eligible students, then the graduate student spoke with the provider to 
determine the reasons for not offering the HPV vaccine and discuss a plan for improvement. 
Organizational Barriers and Facilitators 
The primary barrier was that the HPV vaccine is not included in the requirements for 
university attendance. Additionally, clinical rotations do not ask for it, providing no impetus for 
the clinic to enforce the HPV vaccine. The university does not track the HPV vaccine in student 
records or the student clinic, and assessments for the HPV vaccine are not routinely completed. 
Moreover, men are almost never offered the vaccine although HPV occurs in men; this practice 
does not correlate with the ACHA guidelines, which represent the benchmark to which 
university student health clinics are held. The ACHA guidelines refer to the CDC guidelines as a 
resource regarding which immunizations should be administered within the college setting. As 
for organizational facilitators, the clinical manager and the Dean for Practice & Engagement 
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supported the provision of the HPV vaccine. Stakeholders understood the importance of the 
vaccine and wished to comply with the ACHA guidelines; thus, they were eager to promote HPV 
vaccine implementation.  
Ethical Considerations 
 An ethical issue identified in the literature was the belief that the vaccine would cause 
individuals to be sexually active (CDC, 2016). Furthermore, vaccination does not prevent other 
sexually transmitted infections, as the HPV vaccine does not protect against sexually transmitted 
diseases; thus, additional protection through condom use should be encouraged. Staff and student 
education are therefore imperative to dispelling biased and non-evidence-based beliefs. 
Results 
Objective 1: One hundred percent of providers and staff would be educated on the 
importance of the HPV vaccine and the new vaccination program. [Goal met.]  
All providers and staff completed the HPV PowerPoint education and the pre- and post-
tests (see Appendix A). Staff scores improved by 33% from pre- to post-test; however, barriers 
were encountered. A Health Department representative was originally scheduled to present the 
PowerPoint to the staff with, but many staff were occupied with patients and not enough were 
available at the time of the presentation. Then, a PowerPoint voiceover link was provided as an 
alternative to the live presentation, but no staff took advantage of this mode of presentation. 
Lastly, a paper copy of the PowerPoint was provided to the staff. The staff still stated they were 
too busy to complete the PowerPoint education and post-test; education completion was hence 
delayed. 
Objective 2: Provider recommendations for the HPV vaccine to eligible students would 
increase from 0% initially to 50% post-implementation. [Goal not met.] 
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Of 205 student visits during the implementation period, providers offered 10.7% of 
students the vaccine (see Figure 5). All student visits were included; therefore, students who may 
have completed the series prior to matriculating into the university were included in the total. 
Figure 5. Percentage of provider HPV vaccine recommendations (N = 205). 
Objective 3: The number of eligible students offered the HPV vaccine who received a 
dose would increase from 0% initially to 50% post-intervention. [Goal met.] 
 Sixty-four percent of eligible students who were offered the HPV vaccine received the 
immunization (see Figure 6). Students who had completed the HPV series prior to matriculating 
were not included in the total because they were not considered eligible for the vaccine at the 
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Objective 4: HPV vaccination rates among eligible students who visited the student 
health clinic would increase from 0% initially to 60% post-intervention. [Goal not met.] 
The overall clinic vaccination rate post-implementation was 4.5% (n = 197), assuming 
that all 197 students not offered the HPV vaccine were eligible for it and had not completed the 
HPV series prior to matriculating. 
Discussion 
Taking the above objectives as an outline for the HPV implementation project in the 
student health clinic, each objective will be discussed in detail. 
Objective 1 
The main objective was to increase awareness of the HPV vaccine and the new HPV 
vaccination program. A major component of the corresponding education was to emphasize that 
both sexes can receive the vaccine as a preventative measure for genital warts as well as 
oropharyngeal, anal, and cervical cancers. Ages for eligibility were also reviewed. The desired 
outcome was to educate 100% of clinic providers and staff.  This objective was measured by 
comparing knowledge before the presentation to knowledge gained post-presentation 
intervention by conducting a pre- and post-test. The pre- and post-test instrument was reliable 
and valid according to city health department personnel.  
The objective for this part of the HPV project was met, representing an important 
milestone in the project. All providers and staff increased their knowledge of the HPV vaccine 
and the new program. Therefore, the PowerPoint presentation was useful in providing staff 
meaningful knowledge about the implementation of the HPV vaccine. Challenges in 
implementing this part of the intervention included a lag time in completing the education 
component, which delayed the project start. The scheduled date on which city health department 
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personnel came to perform a presentation at the clinic was not a practical use of time, per the 
clinical manager, and not all staff members could attend the meeting at the same time.  The 
scheduled presentation was canceled due to poor attendance. Time constraints in the clinic 
rendered it difficult for staff to complete a 20-minute voiceover presentation. Staff also stated 
they were too busy to complete the pre-test and post-test; thus, they were encouraged to increase 
completion. Whole-staff completion of the education component of the HPV intervention project 
was time-consuming.  
Objective 2 
Another main objective was to increase the rate at which clinic providers offered the 
HPV vaccine to eligible students, increasing from a pre-intervention rate of 0% to 50% by 
completion of the project. The method of measurement was to assess the number of total 
appointments compared to information collected on the HPV checklists completed by providers 
each week. This objective was not met due to many missed opportunities by providers to 
recommend the HPV vaccine to eligible students. Providers stated they did not remember to 
encourage eligible students to receive the vaccine. Other difficulties included a lack of pop-up 
reminders in the electronic medical record system. Also, providers did not feel that 
recommending the HPV vaccine was the main priority for patients who were being seen for a 
different reason.  
Some successes included the staff being able to follow the processes of providing 
students with HPV-related education and having them sign the consent form. Once students 
signed the consent form, then the RN or LVN administered the HPV vaccine. Finally, students 
were given a reminder card to place in their wallet after the MA scheduled their next visit. 
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Objective 3 
 The next objective was to increase the vaccination rate among eligible students who were 
offered the vaccine from 0% to 50%. This objective was met. A success and strength of the HPV 
vaccination project involved adult students’ ability to make an informed decision about whether 
to receive the HPV vaccine based on recommendations and education from the provider. 
Challenges included that some students did not know if they had received the HPV vaccination 
previously or how many doses they had received. Many university students stated they would 
need to check their immunization records to determine if they needed the HPV vaccine. Other 
students were not interested in receiving the vaccine despite efforts to educate them on its 
importance. Some students stated they were dose-complete.  
Objective 4 
The final objective was to increase the overall HPV vaccination rate among eligible 
students by 60% post-intervention. In the interest of time, the focus was on the first-dose 
initiation. This objective was measured by documenting how many people received at least one 
dose of the HPV vaccine during the implementation period. This objective was not met. 
Difficulties included providers not acknowledging the importance of offering the HPV vaccine. 
They felt they did not have enough time to address each eligible student’s chief complaint and 
recommend the HPV vaccine. In addition, despite an extensive HPV vaccination marketing 
campaign, the effects of such advertising were minimal.  
Limitations  
 An education-related limitation during the first part of the HPV project emerged when the 
initial mode of presenting education to providers and staff was ineffective, resulting in varied 
education attempts. First, a presentation with a health department representative was scheduled 
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but was not attended. Many providers worked on different days, making it difficult to find a time 
that accommodated their busy schedules. Thus, an audio accompaniment was offered to staff as 
an independent alternative; however, staff reported issues accessing the audio PowerPoint, which 
increased the lag time for education completion among providers and staff. The last option was a 
printed PowerPoint for the staff to read. Providers and staff needed time to complete the pre-test, 
education, and post-test. Many reminders from the DNP student and a staff luncheon were 
offered before all providers and staff completed education and testing.   
 Additional limitations included providers not prioritizing offering the HPV vaccine to 
eligible students. Although providers understood evidence-based research and that the vaccine 
was part of the ACHA guidelines, they felt that the student’s chief complaint was the primary 
purpose for the visit, and telling the student about the HPV vaccine took time away from the 
presenting problem. Another problem was that the clinic continued to run out of stock of the 
HPV vaccine during the implementation period. Lastly, students could not remember their HPV 
vaccination status and thus had to decline the HPV vaccine when it was offered. Finally, the 
reimbursement process when offering the HPV vaccine to university students needed to be 
clarified. The clinic did not receive full reimbursement for the vaccine, likely due to entering the 
wrong code when billing insurance companies. 
Recommendations 
 Recommendations for the education component of the HPV vaccine implementation 
program are to keep it simple for staff to complete. A paper copy of the PowerPoint would be an 
ideal way to disseminate information among staff to be read at their convenience. More research 
is needed regarding motivating staff to complete educational offerings; flexibility and patience 
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appear to be key in this regard.  Additionally, the CDC website and local public health 
department should help providers remain abreast of the most up-to-date information.  
 Some suggestions to increase the rate of recommending the HPV vaccine to eligible 
students include incorporating HPV vaccine eligibility and assessment into the electronic 
medical record. This strategy will allow standardization of an assessment for required and 
recommended student vaccinations. Another way to increase the vaccination rate among eligible 
students includes encouragement by the clinical manager to enforce this policy among providers 
in the student health clinic. Lastly, the addition of a reimbursement plan or a benefits coordinator 
would facilitate higher HPV vaccination rates.  
Implications for Practice 
 The providers at the university clinic are aware of the consequences of not following 
evidence-based guidelines when it comes to the primary care of health professions students. 
Enlightening providers and staff about this aspect of care could potentially decrease morbidity 
and mortality among the university student population. An additional implication is financial; 
this HPV project included insurance reimbursement and ensuring the clinic received funds for 
administration of the HPV vaccine. Lastly, in terms of a provider-focused initiative, university 
students may be more likely to consent to receive the HPV vaccine, if their primary care provider 
recommends it.  
 For this project, the DNP-prepared nurse practitioner student applied evidence-based 
scientific knowledge to the healthcare setting (Essential I). Inter-professional cooperation was 
required for a collaborative project such as this; the DNP student worked with MAs, LVNs, RNs, 
and providers (Essential VI). The project coordinator recognized gaps and missed opportunities 
in the healthcare system and arranged a process improvement plan to address these deficits, 
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reinforcing that DNPs are in a position to lead change for the better (Essential II). Using weekly 
audits as a means of collecting and tracking data is reflective of the ways in which a DNP-
prepared nurse can harness healthcare information technology to improve healthcare (Essential 
IV). The university student clinic had never had an HPV vaccination program; launching one 
required policy development and modifications to clinical decision making and related processes 
(Essential V). Overall, increasing the HPV vaccination rate is expected to lead to positive long-
term outcomes, such as increasing students’ protection against HPV and its subsequent 
morbidities.  
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Appendix A  
Education Pre- and Post-Test 
HPV Education Test 












    
True False Not Sure: HPV can affect anyone of any age? 
 
True False Not Sure: The HPV vaccince is not light sensitive and can be kept close to the 
light? 
 
True False Not Sure: The HPV vaccine is only a 3 does series? 
 
True False Not Sure: The purpose of the HPV vaccine  is to help prevent certain types of 
cancer? 
 
True False Not Sure: Only girls need to receive the HPV vaccine? 
 
True False Not Sure: HPV cannot be passsed by skin-to-skin contact? 
 
True False Not Sure: The HPV vaccine is a live antigen? 
 
Primary TVFC Contact Secondary TVFC Contact Clinic or Office Manager 
 
Patient Care Staff (Physician, Nurse, PA, MA) Front Desk Staff/Administrative/Billing Staff 
What is your current role or title with this practice? (Circle all that apply) 
Provider/Clinic Name: TVFC
Please circle true or false for the questions below. 
If you are unsure please circle “Not Sure”. Thus will help us better understand the areas that need 
